1[1]Maini RN,Breedveld FC,Kalden JR,et al.Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis[J].Arthritis Rheum,1998,41:1552. 被引量：1
2[2]Maini R,St Clair EW,Breedveld F,et al.Infliximab (chimeric antitumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate:randomized phase Ⅲ trial:attract study group[J].Lancet,1999,354:1932. 被引量：1
3[3]St Clai EW,van der Heijde D,Smolen J,et al.Combination of infliximab and methotrexate therapy for early rheumatoid arthritis:a randomized,controlled trial[J].Arthritis Rheum,2004,50:3432. 被引量：1
4[4]U Lange,J Teichmann,Mulle Ladner U,et al.Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-antibody:a prospective open-label pilot study[J].Rheumatology,2005,44:1546. 被引量：1
5[5]PC Taylor,A Steuer,J Gruber,et al.Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one year delayed addition of Infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis[J].Arthritis rheumatism,2006,54:47. 被引量：1
6[6]Carrasco R,Smith JA,Lovell D.Biologic agents for the treatment of juvenile rheumatoid arthritis:current status[J].Paediatr Drugs,2004,6:137. 被引量：1
7[7]Gerloni V,Pontikaki I,Gattinara M,et al.Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody,infliximab,in persistently active,refractory juvenile idiopathic arthritis:results of an open-label prospective study[J].Arthritis Rheum,2005,52:548. 被引量：1
8[8]Braun J,Brandt J,Listing J,et al.Treatment of active ankylosing spondylitis with infliximab:a randomized controlled multicentre trial[J].Lancet,2002,359:1187. 被引量：1
9[9]Braun J,Brandt J,Listing J,et al.Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis[J].Ann Rheum Dis,2005,64:229. 被引量：1
10[10]Braun J,Baraliakos X,Brandt J,et al.Persistant clinical response to the anti-TNF alpha antibody infiiximab in patients with anylosing spondylitis over 3 years[J].Rheumatology,2005,44:670. 被引量：1
